We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002001:SZSEZhejiang NHU Company Ltd. Analysis

Data as of 2026-05-24 - not real-time

CN¥31.59

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Zhejiang NHU is trading below its 20‑day simple moving average while still above the identified support level, suggesting a modest upside cushion. The RSI sits in the high‑30s, hinting at a slight oversold condition, and the MACD histogram remains negative, reinforcing a short‑term bearish bias. Fundamentally, the company delivers solid revenue growth, strong operating margins and a healthy cash position, with debt levels comfortably covered by cash. The price‑to‑earnings multiple is well below the industry average, and the discounted cash‑flow model indicates a fair value substantially higher than the current market price, pointing to an undervalued equity. Dividend sustainability looks robust given a payout ratio under one‑third and strong free cash flow generation.
The stock exhibits elevated 30‑day volatility and a decreasing volume trend, which adds execution risk, yet its beta near zero suggests limited market‑wide correlation. With a solid dividend yield, attractive valuation and resilient fundamentals, the stock presents a compelling entry point for investors comfortable with sector‑specific and geographic exposure.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Price near support with upside potential to resistance
  • RSI indicating mild oversold condition
  • Strong cash generation supporting dividend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervaluation relative to peers and DCF fair value
  • Sustained revenue growth and high operating margins
  • Attractive dividend yield with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Fundamental resilience and solid ROE
  • Continued expansion in specialty pharma and nutrition segments
  • Long‑term upside from valuation gap and stable cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth15.70%
Profit Margin29.05%
P/E Ratio14.4
ROE20.44%
ROA10.65%
Debt/Equity21.31
P/B Ratio2.8
Op. Cash FlowCN¥8.9B
Free Cash FlowCN¥5.7B
Industry P/E27.6

Technical Analysis

TrendNeutral
RSI39.8
SupportCN¥30.60
ResistanceCN¥35.60
MA 20CN¥33.19
MA 50CN¥34.88
MA 200CN¥27.67
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair ValueCN¥47.32
Target PriceCN¥38.07
Upside/Downside20.52%
GradeUndervalued
TypeBlend
Dividend Yield3.17%

Risk Assessment

Beta-0.03
Volatility41.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.